Thus, the treatment of tumour-bearing animals with hMSCs does not modify the global number of CD31 and αvß3-integrin positive tumour cells, nor does it change the blood content of the tumours, but it does affect the structure and shape of the blood vessels. Here, PECAM1 is linked to neoplasm.